GURUFOCUS.COM » STOCK LIST » USA » NAS » Vir Biotechnology Inc (NAS:VIR) » Definitions » GF Value Rank
Switch to:

Vir Biotechnology (NAS:VIR) GF Value Rank

: 2 (As of Today)
View and export this data going back to 2019. Start your Free Trial

Vir Biotechnology has the GF Value Rank of 2.

The GF Value Rank is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Vir Biotechnology (NAS:VIR) GF Value Rank Competitive Comparison

For the Biotechnology subindustry, Vir Biotechnology's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Vir Biotechnology (NAS:VIR) GF Value Rank Distribution

For the Biotechnology industry and Healthcare sector, Vir Biotechnology's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Vir Biotechnology's GF Value Rank falls into.



Vir Biotechnology GF Value Rank Related Terms

Thank you for viewing the detailed overview of Vir Biotechnology's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Vir Biotechnology (NAS:VIR) Business Description

Vir Biotechnology logo
Traded in Other Exchanges
Address
499 Illinois Street, Suite 500, San Francisco, CA, USA, 94158
Vir Biotechnology Inc is a commercial-stage immunology company focused on treating and preventing infectious diseases. It has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA, through internal development, collaborations, and acquisitions. The company's pipeline consists of product candidates targeting hepatitis B virus, or HBV, influenza A, human immunodeficiency virus, or HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue and license revenue.
Executives
Friedl-naderer Johanna officer: Chief Business Officer, Global C/O VIR BIOTECHNOLOGY, INC. 499 ILLINOIS STREET, SUITE 500 SAN FRANCISCO CA 94158
Arch Venture Partners Ix Overage, L.p. 10 percent owner 8755 W. HIGGINS ROAD SUITE 1025 CHICAGO IL 60631
Crandell Keith 10 percent owner 8755 W. HIGGINS ROAD SUITE 1025 CHICAGO IL 60631
Nelsen Robert director, 10 percent owner 8755 W. HIGGINS ROAD SUITE 1025 CHICAGO IL 60631
Bybee Clinton 10 percent owner 8755 W. HIGGINS ROAD SUITE 1025 CHICAGO IL 60631
Arch Venture Fund Ix Overage, L.p. 10 percent owner 8725 W. HIGGINS ROAD, SUITE 290 CHICAGO IL 60631
Arch Venture Fund Ix, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631
Arch Venture Partners Ix, L.p. 10 percent owner 8755 W. HIGGINS ROAD SUITE 1025 CHICAGO IL 60631
Arch Venture Partners Ix, Llc 10 percent owner 8755 W. HIGGINS ROAD SUITE 1025 CHICAGO IL 60631
Hanly Ann M. officer: Chief Technology Officer C/O VIR BIOTECHNOLOGY, INC. 499 ILLINOIS STREET, SUITE 500 SAN FRANCISCO CA 94158
Hatfield Jeffrey S. director 11080 ROSELLE STREET SAN DIEGO CA 92121
Napolitano Janet director C/O VIR BIOTECHNOLOGY, INC. 499 ILLINOIS STREET, SUITE 500 SAN FRANCISCO CA 94158
Rice Steven J. officer: Chief Administrative Officer C/O VIR BIOTECHNOLOGY, INC. 499 ILLINOIS STREET, SUITE 500 SAN FRANCISCO CA 94158
Sigal Charles Elliott director 32 BREARLY ROAD PRINCETON NJ 08540
V-sciences Investments Pte Ltd 10 percent owner 60B ORCHARD ROAD #06-18 THE [email protected] SINGAPORE U0 238891

Vir Biotechnology (NAS:VIR) Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
premium membership